GH vs. EXAS

Last updated Apr 1, 2026

Compare and contrast key facts about Guardant Health, Inc. (GH) and Exact Sciences Corporation (EXAS).

Performance

GH vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Guardant Health, Inc. (GH) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

GH vs. EXAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
GH Guardant Health, Inc.	-9.57%	234.34%	12.94%	-0.55%	-72.81%	-22.39%	64.93%	107.87%	16.74%
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	-12.91%

Fundamentals

Market Cap GH : $11.88B EXAS : $19.91B
EPS GH : -$3.30 EXAS : -$1.10
PS Ratio GH : 11.85 EXAS : 6.12
Total Revenue (TTM) GH : $982.02M EXAS : $3.25B
Gross Profit (TTM) GH : $633.01M EXAS : $2.26B
EBITDA (TTM) GH : -$375.72M EXAS : $42.61M

Returns By Period

In the year-to-date period, GH achieves a -9.57% return, which is significantly lower than EXAS's 3.30% return.

GH

• 1D: 7.16%
• 1M: -1.63%
• YTD: -9.57%
• 6M: 47.84%
• 1Y: 116.83%
• 3Y*: 57.95%
• 5Y*: -10.06%
• 10Y*: —

EXAS

• 1D: 0.00%
• 1M: 1.48%
• YTD: 3.30%
• 6M: 91.76%
• 1Y: 142.34%
• 3Y*: 16.54%
• 5Y*: -3.61%
• 10Y*: 32.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GH vs. EXAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GH

GH Risk / Return Rank: 90
GH Sharpe Ratio Rank: 91
GH Sortino Ratio Rank: 91
GH Omega Ratio Rank: 88
GH Calmar Ratio Rank: 91
GH Martin Ratio Rank: 89

EXAS

EXAS Risk / Return Rank: 96
EXAS Sharpe Ratio Rank: 96
EXAS Sortino Ratio Rank: 98
EXAS Omega Ratio Rank: 97
EXAS Calmar Ratio Rank: 92
EXAS Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GH vs. EXAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GH	EXAS	Difference
Sharpe ratio Return per unit of total volatility	2.05	2.80	-0.75
Sortino ratio Return per unit of downside risk	2.91	4.37	-1.46
Omega ratio Gain probability vs. loss probability	1.36	1.64	-0.28
Calmar ratio Return relative to maximum drawdown	3.97	4.40	-0.42
Martin ratio Return relative to average drawdown	9.89	15.32	-5.43
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GH vs. EXAS - Sharpe Ratio Comparison

The current GH Sharpe Ratio is 2.05, which is comparable to the EXAS Sharpe Ratio of 2.80. The chart below compares the historical Sharpe Ratios of GH and EXAS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GH	EXAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.05	2.80	-0.75
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.15	-0.07	-0.08
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.55	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.11	+0.11

Correlation

The correlation between GH and EXAS is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

GH vs. EXAS - Dividend Comparison

Neither GH nor EXAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GH vs. EXAS - Drawdown Comparison

The maximum GH drawdown since its inception was -91.03%, smaller than the maximum EXAS drawdown of -98.01%. Use the drawdown chart below to compare losses from any high point for GH and EXAS.

Drawdown Indicators

	GH	EXAS	Difference
Max Drawdown Largest peak-to-trough decline	-91.03%	-98.01%	+6.98%
Max Drawdown (1Y) Largest decline over 1 year	-28.73%	-29.56%	+0.83%
Max Drawdown (5Y) Largest decline over 5 years	-90.30%	-78.21%	-12.09%
Max Drawdown (10Y) Largest decline over 10 years	—	-80.42%	—
Current Drawdown Current decline from peak	-48.43%	-32.32%	-16.11%
Average Drawdown Average peak-to-trough decline	-51.83%	-49.80%	-2.03%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.54%	8.48%	+3.06%

Volatility

GH vs. EXAS - Volatility Comparison

Guardant Health, Inc. (GH) has a higher volatility of 12.82% compared to Exact Sciences Corporation (EXAS) at 1.18%. This indicates that GH's price experiences larger fluctuations and is considered to be riskier than EXAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GH	EXAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.82%	1.18%	+11.64%
Volatility (6M) Calculated over the trailing 6-month period	40.43%	28.31%	+12.12%
Volatility (1Y) Calculated over the trailing 1-year period	57.26%	44.22%	+13.04%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	67.05%	54.53%	+12.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	68.17%	59.98%	+8.19%

Financials

GH vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between Guardant Health, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Guardant Health, Inc. reported a gross profit of 181.77M and revenue of 281.27M. Therefore, the gross margin over that period was 64.6%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

GH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Guardant Health, Inc. reported an operating income of -120.81M and revenue of 281.27M, resulting in an operating margin of -43.0%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

GH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Guardant Health, Inc. reported a net income of -128.49M and revenue of 281.27M, resulting in a net margin of -45.7%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.